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Abstract
Introduction: Systemic sclerosis (SSc) is characterized by fibrosis and microvascular abnormalities including
dysregulated angiogenesis. Chemokines, in addition to their chemoattractant properties, have the ability to
modulate angiogenesis. Chemokines lacking the enzyme-linked receptor (ELR) motif, such as monokine induced by
interferon-g (IFN-g) (MIG/CXCL9) and IFN-inducible protein 10 (IP-10/CXCL10), inhibit angiogenesis by binding
CXCR3. In addition, CXCL16 promotes angiogenesis by binding its unique receptor CXCR6. In this study, we
determined the expression of these chemokines and receptors in SSc skin and serum.
Methods: Immunohistology and enzyme-linked immunosorbent assays (ELISAs) were used to determine
chemokine and chemokine receptor expression in the skin and serum, respectively, of SSc and normal patients.
Endothelial cells (ECs) were isolated from SSc skin biopsies and chemokine and chemokine receptor expression was
determined by quantitative PCR and immunofluorescence staining.
Results: Antiangiogenic IP-10/CXCL10 and MIG/CXCL9 were elevated in SSc serum and highly expressed in SSc
skin. However, CXCR3, the receptor for these chemokines, was decreased on ECs in SSc vs. normal skin. CXCL16
was elevated in SSc serum and increased in SSc patients with early disease, pulmonary arterial hypertension, and
those that died during the 36 months of the study. In addition, its receptor CXCR6 was overexpressed on ECs in
SSc skin. At the mRNA and protein levels, CXCR3 was decreased while CXCR6 was increased on SSc ECs vs. human
microvascular endothelial cells (HMVECs).
Conclusions: These results show that while the expression of MIG/CXCL9 and IP-10/CXCL10 are elevated in SSc
serum, the expression of CXCR3 is downregulated on SSc dermal ECs. In contrast, CXCL16 and CXCR6 are elevated
in SSc serum and on SSc dermal ECs, respectively. In all, these findings suggest angiogenic chemokine receptor
expression is likely regulated in an effort to promote angiogenesis in SSc skin.
Introduction
Systemic sclerosis (scleroderma, SSc) is a multisystem
disorder that is characterized by fibrosis of the skin and
internal organs, early inflammation, and vascular altera-
tions. As the disease progresses, a loss of vasculature is
observed in many organs, including the skin [1]. How-
ever, despite the loss of vasculature, compensatory angio-
genesis is dysregulated and does not occur normally [2].
Angiogenesis is a highly regulated process of new
blood vessel formation from pre-existing vessels. It is
initiated by either proangiogenic mediators which pro-
mote the release of proteolytic enzymes or those that
activate endothelial cells (ECs), inducing proliferation or
migration [3]. Several types of proangiogenic mediators
have been identified including growth factors, cytokines,
and chemokines.
Chemokines are a family of small proteins that have
leukocyte activation and chemoattractant properties. In
addition, we and others have shown that some chemo-
kines modulate angiogenesis [4,5]. CXC chemokines
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containing the ELR motif (Glu-Leu-Arg), such as inter-
leukin-8 (IL-8/CXCL8), are potent angiogenic factors
[5]. In addition, CXCL16 is a proangiogenic chemokine
that promotes angiogenesis by binding CXCR6 on the
surface of ECs [6]. By contrast, CXC chemokines lacking
the ELR motif, including monokine induced by inter-
feron-g (MIG/CXCL9) and interferon-g inducible pro-
tein 10 (IP-10/CXCL10), are natural inhibitors of
angiogenesis [5]. These chemokines inhibit angiogenesis
by binding CXCR3 on the surface of ECs [7].
In SSc, previous studies have suggested a net increase
in proangiogenic factors locally in the skin and systemi-
cally in the serum, including the overexpression of select
chemokines [8]. Of these, several proangiogenic chemo-
kines are upregulated in SSc serum including IL-8/
CXCL8, growth-regulated oncogene-a (Gro-a/CXCL1),
and monocyte chemoattractant protein-1 (MCP-1/
CCL2) [9-14]. In addition, potent antiangiogenic chemo-
kines such as platelet factor 4 (PF4/CXCL4) [15] and
IP-10/CXCL10 [16] have been shown to be upregulated
in SSc serum. However, the expression of their receptors
has not been examined. Therefore, we examined the
expression of antiangiogenic MIG/CXCL9 and IP-10/
CXCL10, and proangiogenic CXCL16 in SSc serum and
skin, and their receptors in SSc skin and on ECs derived
from the skin of patients with SSc. Our results suggest
that while both pro- and antiangiogenic chemokines are
elevated systemically in SSc, their receptors may be
regulated in an effort to promote angiogenesis in SSc
skin.
Materials and methods
Patients and controls
SSc patient and normal volunteer characteristics are
given in Table 1. Punch biopsy skin samples (4 mm)
were obtained from subjects with SSc and normal volun-
teers. Two biopsies were taken from SSc patients, one
from the proximal arm, which was less clinically involved,
and the other from the distal forearm, which was more
clinically involved [17]. One biopsy was taken from the
forearm of healthy control subjects. Peripheral blood
samples were also collected. All SSc patients fulfilled the
American College of Rheumatology criteria for classifica-
tion of SSc and also met the criteria for diffuse SSc [18].
Biopsies were taken after informed consent, and this
study was approved by the University of Michigan Insti-
tutional Review Board. Complete medical histories were
also taken at the time of biopsy, which included age, dis-
ease duration, and the presence of immunomodulating
therapy. Clinical symptoms were defined as: interstitial
lung disease = ground glass opacification or evidence of
pulmonary fibrosis by high resolution computed tomo-
graphy; renal disease = history of hypertensive sclero-
derma renal crisis; pulmonary arterial hypertension =
determined by right heart catheterization; digital ulcers =
ischemic ulcer on digital tip; gastrointestinal disease =
esophageal dysmotility or small intestinal dysmotility;
gastric antral vascular ectasia = diagnosed by endoscopy.
Patients were also stratified according to early (less than
five years) or late (greater than five years) disease and
those that died during the 36-month study.
Immunohistology
We performed immunohistologic staining on cryosections
from SSc and normal skin, as described previously [19].
Antibodies against MIG/CXCL9 (R&D Systems, Minneapo-
lis, MN, USA), IP-10/CXCL10 (Peprotech, Rocky Hill, NJ,
USA), CXCL16 (Peprotech), CXCR3 (R&D Systems), and
CXCR6 (R&D Systems) were used as primary antibodies.
Purified nonspecific isotype matched IgG was used as a
control. An antibody against von Willebrand factor (vWF)
was used to confirm the presence of ECs in normal and SSc
skin sections as previously described [17]. Staining was eval-
uated in duplicate under blinded conditions and graded by
a pathologist. Entire tissue sections were examined for cel-
lular immunoreactivity and cell types were distinguished
based on their characteristic morphology. For quantifica-
tion, the percentage of positive cells was calculated as
stained cells in proportion to all cells of a distinctive subset.
Table 1 SSc patient and normal volunteer characteristics
SSc patients Normal
volunteers
Age (years) 52.5 ± 1.8a 51.2 ± 4.4
Women 18 3
Men 2 7
Diffuse SSc 19 NAb
Raynaud’s 19 NA
Disease duration (years) 3.7 ± 0.8 NA
Early diseasec 13 NA
Late disease 7 NA
Deceased 4 NA
Renal involvement 1 NA
Interstitial lung disease 10 NA
Pulmonary arterial
hypertension
2 NA
Digital ulcers 10 NA
Gastrointestinal disease 19 NA
Gastric antral vascular ectasia 3 NA
Immunomodulatory therapy 3 NA
SSc patients serum CXCL16 (ng/ml)
With Without
Pulmonary arterial
hypertension
5.7 ± 1.2 (n = 2)d 4.5 ± 0.1 (n = 18)
Early disease 4.9 ± 0.2 (n = 13)d 4.0 ± 0.1 (n = 7)
Deceased 5.6 ± 0.4 (n = 4)d 4.4 ± 0.1 (n = 16)
aMean ± SEM. bNA = Not applicable. cEarly disease = less than five years.
dP < 0.05.
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Enzyme-linked immunosorbent assays (ELISAs)
Commercial ELISA kits were purchased and used fol-
lowing the manufacturer’s instructions to determine the
concentrations of IP-10/CXCL10 (Invitrogen, Carlsbad,
CA, USA), CXCL16 (Peprotech), and MIG/CXCL9
(R&D Systems) in SSc and normal serum.
Isolation of ECs from SSc skin
Microvascular ECs from SSc skin were isolated as pre-
viously described [20,21]. Briefly, the epidermis and sub-
cutaneous layers were mechanically removed from skin
biopsies, leaving the vascularized dermal layer. Micro-
vascular colonies were selected and ECs were positively
selected using Dynabeads CD31 (Invitrogen). Confirma-
tion of EC selection was made using antibodies against
CD31 and von Willebrand factor (vWF).
SSc EC and human dermal microvascular endothelial cell
(HMVEC) cell culture
HMVECs were obtained from Lonza (Basel, Switzerland)
and cultured using complete EC basal medium (EBM)-2
medium with 5% FBS and EC growth medium-2 Single-
Quots (Lonza) as previously described [22]. SSc ECs
were cultured in complete EBM-2 media with EC
growth medium-2 SingleQuots with 20% FBS. HMVECs
and SSc ECs were used between passage 5 and 11. SSc
ECs and HMVECs were plated on gelatin coated six-
well plates and grown to confluence. The cells were
serum starved overnight in EBM media with 0.1% FBS
prior to RNA isolation.
RNA isolation and quantitative PCR (qPCR)
Total RNA was extracted from SSc ECs and HMVECs
and qPCR was performed using a Mastercycler ep real-
plex (Eppendof, Hauppauge, NY, USA) as previously
described [23]. The primer sets used were CXCR3
5’TGGCCGAGAAAGCAGGG3’ and 5’AGGCGCAA-
GAGCAGCATC3’; CXCR6 5’ATGGCAATGTCTT-
TAATCTCGACAA3’ and 5’TGAAAGCTGGTCATGGC
ATAGTATT3’; and CXCL16 5’ACTACACGAGGTTC-
CAGCTCC3’ and 5’CTTTGTCCGAGGACAGTGATC3’
[24,25]. Primers specific for b-actin were used as a
control.
Immunofluorescence
Immunofluorescence staining was performed as pre-
viously described [26]. Primary antibodies specific for
vWF (Dako, Glostrup, Denmark), CXCR3 (R&D Sys-
tems), CXCR6 (R&D Systems), or mouse IgG (Thermo-
Fisher, Waltham, MA, USA) (10 μg/ml) were used.
Binding was detected using Alexa Fluor 555-conjugated
donkey anti-mouse antibody (Molecular Probes, Eugene,
OR, USA) and 4’,6-diaminido-2-phenylindole (DAPI,
Molecular Probes) nuclear stain was added to observe
nuclei. Staining was detected using an Olympus fluores-
cence microscope (Olympus America, Melville, NY,
USA). Images were taken at 400×.
Statistical analysis
Student’s t-tests and, where appropriate, ANOVAs were
performed, and P-values less than 0.05 were considered
significant. All values presented were the mean ± stan-
dard error of the mean (SEM).
Results
Chemokine expression in SSc serum
Serum from patients with SSc and healthy volunteers
was assayed using ELISAs to determine the expression
of pro- and antiangiogenic chemokines. SSc serum had
significantly elevated levels of antiangiogenic chemo-
kines compared to normal controls (Figure 1A). The
expression of MIG/CXCL9 was significantly greater in
SSc serum (mean 876 pg/ml ± SEM 250 pg/ml) com-
pared to normal serum (126 pg/ml ± 1, P < 0.05). In
addition, IP-10/CXCL10 was significantly elevated in
SSc serum (495 pg/ml ± 38) compared to normal serum
(263 pg/ml ± 53, P < 0.05, Figure 1B). Similar results
were found when a representative proangiogenic chemo-
kine was assayed in SSc and normal serum. The expres-
sion of CXCL16 was significantly greater in SSc serum
(4.6 ng/ml ± 0.2) compared to normal serum (3.3 ng/ml
± 0.1, P < 0.05, Figure 1C). These results demonstrate
that both pro- and antiangiogenic chemokines are sig-
nificantly upregulated in the serum of patients with SSc.
In patients with SSc, CXCL16 was significantly ele-
vated in those with pulmonary arterial hypertension (5.7
ng/ml ± 1.2, n = 2) compared to those without (4.5 ng/
ml ± 0.1, n = 18, P < 0.05, Table 1). CXCL16 was also
significantly increased in SSc patients that died during
the 36 months of the study (5.6 ng/ml ± 0.4, n = 4)
compared to surviving patients (4.4 ng/ml ± 0.1, n = 16,
P < 0.05). Moreover, SSc patients with early disease had
significantly increased levels of CXCL16 (4.9 ng/ml ±
0.2, n = 13) compared to those with late disease (4.0 ng/
ml ± 0.1, n = 7, P < 0.05). However, no differences were
observed in any clinical characteristics with respect to
serum MIG/CXCL9 and IP-10/CXCL10.
Chemokine and chemokine receptor expression in SSc
skin
After finding elevated expression of the antiangiogenic
chemokines MIG/CXCL9 and IP-10/CXCL10 in SSc
serum, we sought to determine their expression, and
the expression of their receptor CXCR3, in SSc skin
(Figure 2). MIG/CXCL9 was primarily expressed in the
stratum spinosum of the epidermis in normal skin (48%
± 15) and both proximal (52% ± 9) and distal SSc skin
(57% ± 8), with no significant differences observed
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among the three groups. MIG/CXCL9 was also
expressed at much lower quantities on normal and SSc
dermal ECs and fibroblasts (data not shown). Similarly,
IP-10/CXCL10 was also highly expressed in the epider-
mal layer stratum basalis in normal skin and proximal
and distal SSc skin (all 100%, Figure 2B). In contrast to
MIG/CXCL9, the expression of IP-10/CXCL10 was not
observed on any other cell types in either normal or SSc
skin. Importantly, while MIG/CXCL9 and IP-10/
CXCL10 were elevated systemically and highly expressed
locally in SSc skin, the expression of their receptor
CXCR3 was decreased (Figure 2C). CXCR3 expression
was restricted to ECs, and was significantly decreased
on ECs in both proximal (25% ± 6) and distal SSc skin
(21% ± 5) compared to normal skin (54% ± 10, P <
0.05). These findings suggest that ECs in SSc may have
a diminished response to these chemokines based on
the downregulation of their receptor.
We also examined the expression of the proangiogenic
chemokine CXCL16 in normal and SSc skin (Figure 3).
CXCL16 was highly expressed in the stratum spinosum
of the epidermis of normal skin (40% ± 10) and proxi-
mal (30% ± 8) and distal SSc skin (39% ± 8). CXCL16
was also expressed on dermal ECs, with its expression
significantly decreased on proximal (18% ± 4) and distal
SSc skin (20% ± 4) compared to normal skin (45% ± 10,
P < 0.05, Figure 3B). Moreover, the expression of its
exclusive receptor, CXCR6, was significantly elevated on
ECs in both proximal (16% ± 3) and distal SSc skin
(15% ± 3) compared to normal skin (4% ± 1, P < 0.05,
Figure 3C). In contrast with the expression of the anti-
angiogenic receptor CXCR3, proangiogenic CXCR6 was
upregulated on ECs in SSc skin.
Chemokine and chemokine receptor expression by SSc
ECs
After determining the expression of pro- and antiangio-
genic chemokines in SSc skin, we isolated ECs from SSc
skin biopsies and examined chemokine receptor expres-
sion at the mRNA level [20]. SSc ECs and HMVECs
were cultured, their mRNA extracted, cDNA prepared,
and quantitative PCR was performed. The mRNA
expression of CXCR3 was decreased and CXCR6 was
increased in SSc ECs, similar to our immunohistological
findings using whole skin biopsies (Table 2).
After finding that EC CXCR3 and CXCR6 were down-
regulated and upregulated, respectively, by immunohis-
tochemistry and quantitative PCR, we performed
immunofluorescence staining on cultured SSc ECs to
visualize the protein expression of these antigens
in vitro. We found that cultured SSc ECs had reduced
expression of the endothelial maker vWF as previously
described (data not shown) [27]. In addition, SSc ECs
showed reduced staining for CXCR3, while the expres-
sion of CXCR6 was not notably increased in SSc ECs
(Figure 4).
Discussion
Angiogenesis in SSc skin does not occur normally
despite the overexpression of proangiogenic mediators
in the skin and serum [2]. Select chemokines, in addi-
tion to their role as chemoattractant molecules, modu-
late angiogenesis. In general, CXC chemokines
containing an ELR motif are angiogenic, while CXC che-
mokines lacking the motif are angiostatic [5]. Several
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Figure 1 MIG/CXCL9, IP-10/CXCL10, and CXCL16 are
overexpressed in SSc serum. The amounts of MIG/CXCL9 (A), IP-
10/CXCL10 (B), and CXCL16 (C) were determined in normal and SSc
serum by ELISA. Means are given with SEM. Differences were
determined using the Student’s t-test and P-values less than 0.05
were significant. n = number of patients.
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other chemokines have been shown to be proangiogenic
including MCP-1/CCL2, macrophage inflammatory pro-
tein-1a (MIP-1a/CCL3), and CXCL16 [7]. Collectively,
these and other studies established the role of chemo-
kines in angiogenesis.
Angiogenic chemokines have previously been asso-
ciated with SSc pathogenesis [8]. We and others have
shown that IL-8/CXCL8 is a potent proangiogenic che-
mokine overexpressed in both SSc serum and skin
[9,11,14,28]. In addition, it has been associated with SSc
lung pathology, as it is elevated in pulmonary bronchial
lavage fluid and secreted by alveolar macrophages [29].
Moreover, the angiogenic CXC chemokines Gro-a/
CXCL1 and stromal derived factor-1 (SDF-1/CXCL12)
have also been found to be upregulated in SSc serum
[9,10,30]. Among CC chemokines that are angiogenic,
MCP-1/CCL2 and MIP-1a/CCL3 have been shown to
be upregulated in SSc [10,12,29]. PF4/CXCL4, which by
contrast is an antiangiogenic chemokine, has also been
shown to be upregulated in SSc serum [15].
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Figure 2 MIG/CXCL9 and IP-10/CXCL10 are highly expressed, but CXCR3 is decreased, in SSc and normal skin. Frozen sections of
proximal and distal SSc and normal skin were stained for MIG/CXCL9, IP-10/CXCL10, or CXCR3. (A), MIG/CXCL9 was highly expressed in the
stratum spinosum of normal (48%), proximal SSc (52%), and distal SSc (57%) skin. (B), IP-10/CXCL10 was uniformly expressed in the stratum
basalis of normal, proximal SSc, and distal SSc skin at 100%. (C), CXCR3 was significantly decreased on ECs in proximal SSc (25%) and distal SSc
skin (21%) compared to normal skin (54%). Representative photos of CXCR3 immunohistological staining in normal (D) and distal SSc skin (E) are
shown. Arrows indicate positive staining. Means are given with the SEM. n = the number of patients. P < 0.05 was considered significant.
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Figure 3 CXCL16 and CXCR6 are highly expressed in SSc compared to normal skin. Frozen sections of proximal and distal SSc and normal
skin were stained for CXCL16 or CXCR6. (A), CXCL16 was highly expressed in the stratum spinosum of normal (40%), proximal SSc (30%), and
distal SSc (39%) skin. (B), CXCL16 was significantly decreased on ECs in proximal SSc (18%) and distal SSc skin (20%) compared to normal skin
(45%). Representative photos of CXCL16 immunohistological staining in normal (C) and distal SSc skin (D) are shown. (E), CXCR6 was significantly
increased on ECs in proximal SSc (16%) and distal SSc skin (15%) compared to normal skin (4%). Representative photos of CXCR6
immunohistological staining in normal (F) and distal SSc skin (G) are shown. Arrows indicate positive staining. Means are given with the SEM.
n = the number of patients. P < 0.05 was considered significant.
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In this study, we examined the expression of select
pro- and antiangiogenic chemokines and their receptors
in SSc. We found that antiangiogenic MIG/CXCL9 was
significantly elevated in SSc serum compared to normal
controls. The only other study to examine its expression
in SSc serum found that MIG/CXCL9 was detected at
similar rates in diffuse and limited SSc serum and nor-
mal control serum [16]. However, the assays employed
in that study were not as sensitive as the methods used
here, as their analysis was limited to detection, whereas
we were able to quantify MIG/CXCL9 expression. We
also found that IP-10/CXCL10 was elevated in SSc
serum compared to normal controls. Similar to our
results, Fujii et al. demonstrated that IP-10/CXCL10
was detected more often in SSc serum compared to
healthy control serum [16]. In addition, a more recent
study has demonstrated that IP-10/CXCL10 is signifi-
cantly elevated in early SSc serum compared to controls,
and that its level significantly decreases after five years
[31]. Moreover, the level of IP-10/CXCL10 correlated
with lung and kidney involvement in SSc patients [31].
In accordance with these findings, we found that both
MIG/CXCL9 and IP-10/CXCL10 were highly expressed
in the epidermis. Mediators produced by keratinocytes
in the epidermis may cross into the dermal layer and
affect the function of fibroblasts and other cell types in
the dermis [32]. This suggests that chemokines
expressed in the epidermis may act on dermal vascula-
ture, along with the circulating chemokines in the
serum.
After examining the expression of the antiangiogenic
chemokines MIG/CXCL9 and IP-10/CXCL10 in SSc
skin and serum, we then sought to determine the
expression of their receptor. The ELR negative chemo-
kines PF4/CXCL4, MIG/CXCL9, and IP-10/CXCL10
mediate their leukocyte chemoattractant and angiogenic
effects by interacting with CXCR3 [7]. To date, three
splice variants of CXCR3 have been identified; CXCR3-
A, CXCR3-B, and CXCR3-alt [33]. However, the angio-
static effects of PF4/CXCL4, MIG/CXCL9, and IP-10/
CXCL10 are mediated solely by CXCR3-B [34,35]. We
found that CXCR3 is decreased on ECs in both proxi-
mal and distal SSc skin compared to normal skin. More-
over, we observed that SSc ECs have reduced mRNA
levels of CXCR3 compared to HMVECs, and that
in vitro CXCR3 cell surface expression is decreased on
SSc ECs compared to HMVECs. Previous studies
describing the expression of CXCR3 on ECs in vitro
have yielded inconsistent results. CXCR3 has been
Table 2 CXCR3 is decreased while CXCR6 is increased on
SSc ECs
Average relative abundancea
HMVECb SSc ECc Ratio
CXCR3 3.8 E-04 ± 9.1 E-06 1.5 E-04 ± 8.8 E-05 0.4
CXCR6 2.2 E-05 ± 1.1 E-05 3.2 E-05 ± 8.1 E-06 1.5
CXCL16 1.1 E-05 ± 1.6 E-06 1.4 E-04 ± 3.7 E-05 13.4
aChemokine or chemokine receptor/b-actin. bn = three replicates. cn = three
patient derived lines. dMean ± SEM.
A.
HMVECs
B.
CXCR3IgG control
SSc ECs
CXCR6
Figure 4 CXCR3 expression is decreased while CXCR6 expression is unchanged on SSc ECs compared to HMVECs. HMVECs (A) and SSc
ECs (B) were cultured on gelatin-coated chambers and immunofluorescence stained. Staining with specific antibodies against CXCR3, CXCR6, or
irrelevant IgG control is shown. Nuclei were counter stained with DAPI. Staining was detected using a fluorescence microscope and images were
taken at 400×.
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shown to be expressed on HMVECs, but not on human
umbilical vein ECs (HUVECs) [33,36]. This may be due
to the different nature of microvascular ECs and venous
ECs, as Chi et al. has previously shown that ECs from
different anatomical sites have disparate gene expression
profiles [37]. Thus HMVECs isolated from adult skin
are a more suitable control population for our SSc ECs
than HUVECs. In addition, differences in cytokine and
growth factor expression may alter CXCR3 expression,
as tumor necrosis factor (TNF)-a downregulates
CXCR3 expression [38]. TNF-a and other proinflamma-
tory cytokines are known to be upregulated in SSc skin
and serum, which may account for the decreased
CXCR3 expression we observed in vitro and in vivo
[12,39,40].
In addition, we also determined the expression of the
proangiogenic receptor CXCR6 and its ligand CXCL16.
CXCL16 is a recently described CXC chemokine that is
found in both membrane bound and soluble forms, the
latter following cleavage by a disintegrin and metallo-
proteinase 10 (ADAM10) [41]. It has a unique receptor
in CXCR6, which the membrane bound form of
CXCL16 binds to facilitate firm adhesion of emigrating
leukocytes, and the soluble form utilizes to mediate its
chemotactic properties [42]. CXCL16 is expressed on a
number of different cell types, including leukocytes, ECs
and keratinocytes [43].
We found that CXCL16 was significantly upregulated
in SSc serum. In addition, it was the only chemokine in
our study that was associated with specific SSc clinical
features. Serum CXCL16 was elevated in SSc patients
that died between the time of biopsy and the time of
data analysis, and in those with pulmonary arterial
hypertension and early disease. A recent study by
Yanaba et al. found similar results and showed that
CXCL16 serum levels correlated with the extent of skin
sclerosis [43]. In addition, they demonstrated that
CXCL16 levels decrease as SSc skin sclerosis improves
[43]. Collectively, these findings implicate CXCL16 as a
chemokine of interest in SSc that warrants further study.
In SSc skin biopsies, we found that CXCL16 was
highly expressed in the stratum spinosum layer of the
epidermis, and decreased on dermal ECs compared to
normal skin. In contrast, our in vitro results indicate
that CXCL16 mRNA is modestly increased in SSc ECs.
It is likely that this discrepancy is caused by the differ-
ences in detection techniques, and the fact that CXCL16
exists in both secreted and membrane bound forms.
The receptor for CXCL16, CXCR6, is expressed by
several cell types, most notably memory and activated T
cells, cancer cells, and ECs [44]. We observed that
CXCR6 was significantly upregulated on dermal ECs in
both proximal and distal SSc skin biopsies. Moreover,
we found a similar expression pattern on cultured SSc
ECs compared to HMVECs. To date, little is known
regarding the regulation of CXCR6 expression. However,
hypoxia has been shown to be a strong inducer of
CXCR6 expression via hypoxia-inducible factor-1a [6].
Hypoxia is a characteristic feature of SSc [45]. In SSc,
the hypoxic environment is thought to be a factor in the
overexpression of potent angiogenic factors such as
VEGF [45]. Likewise, it seems probable that skin
hypoxia could result in an increase of CXCR6 expres-
sion on SSc ECs. In addition, CXCR6-expressing
HUVECs migrate in response to CXCL16 [6]. As EC
chemotaxis is an initial step in the angiogenic cascade,
these findings suggest that CXCL16/CXCR6 may be
important in mediating SSc angiogenesis.
Conclusions
Diminished dermal vasculature and dysregulated angio-
genesis are hallmarks of SSc. Our results indicate a sys-
temic overexpression of proangiogenic CXCL16 and
antiangiogenic MIG/CXCL9 and IP-10/CXCL10 in SSc
serum. However, differential expression of CXCR3 and
CXCR6 was observed on SSc dermal ECs. Collectively,
these results argue that despite high serum levels of
antiangiogenic chemokines, the downregulation of their
receptor on SSc ECs prevents them from directly contri-
buting to the hypovascular state of SSc skin. In addition,
the increase of CXCR6 on SSc ECs points to CXCL16
being a relevant angiogenic factor in SSc that warrants
further study.
Abbreviations
ADAM10: a disintegrin and metalloproteinase 10; DAPI: 4’,6-diaminido-2-
phenylindole; ECs: endothelial cells; ELISA: enzyme-linked immunosorbent
assay; Glu-Leu-Arg: ELR motif; Gro-α/CXCL1: growth-regulated oncogene-α;
HMVECs: human microvascular endothelial cells; HUVECs: human umbilical
vein ECs; IFN-γ: interferon-γ; IL: interleukin; IP-10/CSCL10: IFN-inducible
protein 10; MCP-1/CCL2: monocyte chemoattractant protein-1; MIG/CXCL9:
monokine induced by IFN-γ; MIP-1α/CCL3: macrophage inflammatory
protein-1α; PF4/CXCL4: platelet factor 4; qPCR: quantitative polymerase chain
reaction; SDF-1/CXCL12: stromal derived factor-1; SEM: standard error of the
mean; SSC: systemic sclerosis; vWF: von Willebrand factor.
Acknowledgements
This work was supported by the National Institute of Health (grants
HL094017 to BJR, and AR48267 to AEK), the Office of Research and
Development, Medical Research Service, Department of Veterans Affairs, the
Frederick G. L. Huetwell and William D. Robinson, MD, Professorship in
Rheumatology, Scleroderma Research Foundation (CA), NIH General Clinical
Research Center grant M01-RR-00042, NIH Center for Translational Science
Activities grant UL1-RR-024986, the clinical research unit at the University of
Michigan, American College of Rheumatology Research and Education
Foundation grant (ARA to KP), the Linda Dolce Scleroderma Research Fund,
the Marvin and Betty Danto and the Jonathan and Lisa Rye Endowments for
Scleroderma Research at the University of Michigan, and by the Scleroderma
Foundation (Mark Flapan Award).
Author details
1Department of Internal Medicine, University of Michigan Medical School,
109 Zina Pitcher Dr., Ann Arbor, MI 48109, USA. 2Department of Pathology,
Yale University, 200 South Frontage Rd., New Haven, CT 06510, USA.
3Department of Medicine, University of Toledo, 3000 Arlington Ave., Toledo,
Rabquer et al. Arthritis Research & Therapy 2011, 13:R18
http://arthritis-research.com/content/13/1/R18
Page 8 of 10
OH 43614, USA. 4Current address: Scleroderma Research Consultants, LLC, 97
Deer Run, Avon, CT 06001, USA. 5Department of Veterans Affairs, VA Medical
Service, 2215 Fuller Rd., Ann Arbor, MI 48105, USA.
Authors’ contributions
BJR conceived the study, and participated in the immunohistology, ELISA,
cell culture, qPCR, immunofluorescence, and data analysis and drafted the
manuscript. PT participated in the immunohistology, ELISA, qPCR, and data
analysis. YH participated in the immunohistology and ELISAs. ET participated
in the immunohistology and ELISAs. GKH scored the immunohistology. AJI
performed the statistical analysis. KP conceived the study and collected
clinical data. BK isolated ECs from SSc skin. JRS conceived the study and
collected clinical data. AEK conceived the study and drafted the manuscript.
All authors read and approved the final manuscript.
Competing interests
The authors declare that they have no competing interests.
Received: 31 August 2010 Revised: 10 January 2011
Accepted: 8 February 2011 Published: 8 February 2011
References
1. Gabrielli A, Avvedimento EV, Krieg T: Scleroderma. N Engl J Med 2009,
360:1989-2003.
2. Distler JH, Gay S, Distler O: Angiogenesis and vasculogenesis in systemic
sclerosis. Rheumatology (Oxford) 2006, 45:iii26-27.
3. Szekanecz Z, Gaspar L, Koch AE: Angiogenesis in rheumatoid arthritis.
Front Biosci 2005, 10:1739-1753.
4. Koch AE, Polverini PJ, Kunkel SL, Harlow LA, DiPietro LA, Elner VM, Elner SG,
Strieter RM: Interleukin-8 as a macrophage-derived mediator of
angiogenesis. Science 1992, 258:1798-1801.
5. Strieter RM, Polverini PJ, Kunkel SL, Arenberg DA, Burdick MD, Kasper J,
Dzuiba J, Van Damme J, Walz A, Marriott D: The functional role of the ELR
motif in CXC chemokine-mediated angiogenesis. J Biol Chem 1995,
270:27348-27357.
6. Lin S, Sun L, Hu J, Wan S, Zhao R, Yuan S, Zhang L: Chemokine C-X-C
motif receptor 6 contributes to cell migration during hypoxia. Cancer
Lett 2009, 279:108-117.
7. Strieter RM, Burdick MD, Gomperts BN, Belperio JA, Keane MP: CXC
chemokines in angiogenesis. Cytokine Growth Factor Rev 2005, 16:593-609.
8. Yamamoto T: Chemokines and chemokine receptors in scleroderma. Int
Arch Allergy Immunol 2006, 140:345-356.
9. Furuse S, Fujii H, Kaburagi Y, Fujimoto M, Hasegawa M, Takehara K, Sato S:
Serum concentrations of the CXC chemokines interleukin 8 and growth-
regulated oncogene-alpha are elevated in patients with systemic
sclerosis. J Rheumatol 2003, 30:1524-1528.
10. Hasegawa M, Sato S, Takehara K: Augmented production of
chemokines (monocyte chemotactic protein-1 (MCP-1), macrophage
inflammatory protein-1alpha (MIP-1alpha) and MIP-1beta) in patients
with systemic sclerosis: MCP-1 and MIP-1alpha may be involved in
the development of pulmonary fibrosis. Clin Exp Immunol 1999,
117:159-165.
11. Reitamo S, Remitz A, Varga J, Ceska M, Effenberger F, Jimenez S, Uitto J:
Demonstration of interleukin 8 and autoantibodies to interleukin 8 in
the serum of patients with systemic sclerosis and related disorders. Arch
Dermatol 1993, 129:189-193.
12. Scala E, Pallotta S, Frezzolini A, Abeni D, Barbieri C, Sampogna F, De Pita O,
Puddu P, Paganelli R, Russo G: Cytokine and chemokine levels in systemic
sclerosis: relationship with cutaneous and internal organ involvement.
Clin Exp Immunol 2004, 138:540-546.
13. Yamamoto T, Eckes B, Hartmann K, Krieg T: Expression of monocyte
chemoattractant protein-1 in the lesional skin of systemic sclerosis.
J Dermatol Sci 2001, 26:133-139.
14. Koch AE, Kronfeld-Harrington LB, Szekanecz Z, Cho MM, Haines GK,
Harlow LA, Strieter RM, Kunkel SL, Massa MC, Barr WG, et al: In situ
expression of cytokines and cellular adhesion molecules in the skin of
patients with systemic sclerosis. Their role in early and late disease.
Pathobiology 1993, 61:239-246.
15. Macko RF, Gelber AC, Young BA, Lowitt MH, White B, Wigley FM,
Goldblum SE: Increased circulating concentrations of the
counteradhesive proteins SPARC and thrombospondin-1 in systemic
sclerosis (scleroderma). Relationship to platelet and endothelial cell
activation. J Rheumatol 2002, 29:2565-2570.
16. Fujii H, Shimada Y, Hasegawa M, Takehara K, Sato S: Serum levels of a Th1
chemoattractant IP-10 and Th2 chemoattractants, TARC and MDC, are
elevated in patients with systemic sclerosis. J Dermatol Sci 2004, 35:43-51.
17. Hou Y, Rabquer BJ, Gerber ML, Del Galdo F, Jimenez SA, Haines GK,
Barr WG, Massa MC, Seibold JR, Koch AE: Junctional adhesion molecule-A
is abnormally expressed in diffuse cutaneous systemic sclerosis skin and
mediates myeloid cell adhesion. Ann Rheum Dis 2010, 69:249-254.
18. LeRoy EC, Black C, Fleischmajer R, Jablonska S, Krieg T, Medsger TA Jr,
Rowell N, Wollheim F: Scleroderma (systemic sclerosis): classification,
subsets and pathogenesis. J Rheum 1988, 15:202-205.
19. Rabquer BJ, Hou Y, Del Galdo F, Haines GK, Gerber ML, Jimenez SA,
Seibold JR, Koch AE: The proadhesive phenotype of systemic sclerosis
skin promotes myeloid cell adhesion via ICAM-1 and VCAM-1.
Rheumatology (Oxford) 2009, 48:734-740.
20. D’Alessio S, Fibbi G, Cinelli M, Guiducci S, Del Rosso A, Margheri F, Serrati S,
Pucci M, Kahaleh B, Fan P, Annunziato F, Cosmi L, Liotta F, Matucci-
Cerinic M, Del Rosso M: Matrix metalloproteinase 12-dependent cleavage
of urokinase receptor in systemic sclerosis microvascular endothelial
cells results in impaired angiogenesis. Arthritis Rheum 2004, 50:3275-3285.
21. Scott PA, Bicknell R: The isolation and culture of microvascular
endothelium. J Cell Sci 1993, 105:269-273.
22. Rabquer BJ, Amin MA, Teegala N, Shaheen MK, Tsou P, Ruth JH, Lesch CA,
Imhof BA, Koch AE: Junctional adhesion molecule-C is a soluble mediator
of angiogenesis. J Immunol 2010, 185:1777-1785.
23. Ahmed S, Marotte H, Kwan K, Ruth JH, Campbell PL, Rabquer BJ, Pakozdi A,
Koch AE: Epigallocatechin-3-gallate inhibits IL-6 synthesis and suppresses
transsignaling by enhancing soluble gp130 production. Proc Natl Acad
Sci U S A 2008, 105:14692-14697.
24. Hanamoto H, Nakayama T, Miyazato H, Takegawa S, Hieshima K, Tatsumi Y,
Kanamaru A, Yoshie O: Expression of CCL28 by Reed-Sternberg cells
defines a major subtype of classical Hodgkin’s disease with frequent
infiltration of eosinophils and/or plasma cells. Am J Pathol 2004,
164:997-1006.
25. Notohamiprodjo M, Segerer S, Huss R, Hildebrandt B, Soler D,
Djafarzadeh R, Buck W, Nelson PJ, von Luettichau I: CCR10 is expressed in
cutaneous T-cell lymphoma. Int J Cancer 2005, 115:641-647.
26. Rabquer BJ, Pakozdi A, Michel JE, Gujar BS, Haines GK, Imhof BA, Koch AE:
Junctional adhesion molecule-C mediates leukocyte adhesion to the
rheumatoid arthritis synovium. Arthritis Rheum 2008, 58:3020-3029.
27. Freemont AJ, Hoyland J, Fielding P, Hodson N, Jayson MI: Studies of the
microvascular endothelium in uninvolved skin of patients with systemic
sclerosis: direct evidence for a generalized microangiopathy. Br J
Dermatol 1992, 126:561-568.
28. Kadono T, Kikuchi K, Ihn H, Takehara K, Tamaki K: Increased production of
interleukin 6 and interleukin 8 in scleroderma fibroblasts. J Rheumatol
1998, 25:296-301.
29. Bolster MB, Ludwicka A, Sutherland SE, Strange C, Silver RM: Cytokine
concentrations in bronchoalveolar lavage fluid of patients with systemic
sclerosis. Arthritis Rheum 1997, 40:743-751.
30. Cipriani P, Franca Milia A, Liakouli V, Pacini A, Manetti M, Marrelli A,
Toscano A, Pingiotti E, Fulminis A, Guiducci S, Perricone R, Kahaleh B,
Matucci-Cerinic M, Ibba-Manneschi L, Giacomelli R: Differential expression
of stromal cell-derived factor 1 and its receptor CXCR4 in the skin and
endothelial cells of systemic sclerosis patients: pathogenetic
implications. Arthritis Rheum 2006, 54:3022-3033.
31. Antonelli A, Ferri C, Fallahi P, Ferrari SM, Giuggioli D, Colaci M, Manfredi A,
Frascerra S, Franzoni F, Galetta F, Ferrannini E: CXCL10 (alpha) and CCL2
(beta) chemokines in systemic sclerosis–a longitudinal study.
Rheumatology (Oxford) 2008, 47:45-49.
32. Werner S, Smola H: Paracrine regulation of keratinocyte proliferation and
differentiation. Trends Cell Biol 2001, 11:143-146.
33. Lasagni L, Francalanci M, Annunziato F, Lazzeri E, Giannini S, Cosmi L,
Sagrinati C, Mazzinghi B, Orlando C, Maggi E, Marra F, Romagnani S,
Serio M, Romagnani P: An alternatively spliced variant of CXCR3 mediates
the inhibition of endothelial cell growth induced by IP-10, Mig, and I-
TAC, and acts as functional receptor for platelet factor 4. J Exp Med 2003,
197:1537-1549.
34. Vandercappellen J, Van Damme J, Struyf S: The role of CXC chemokines
and their receptors in cancer. Cancer Lett 2008, 267:226-244.
Rabquer et al. Arthritis Research & Therapy 2011, 13:R18
http://arthritis-research.com/content/13/1/R18
Page 9 of 10
35. Yang J, Richmond A: The angiostatic activity of interferon-inducible
protein-10/CXCL10 in human melanoma depends on binding to CXCR3
but not to glycosaminoglycan. Mol Ther 2004, 9:846-855.
36. Schutyser E, Su Y, Yu Y, Gouwy M, Zaja-Milatovic S, Van Damme J,
Richmond A: Hypoxia enhances CXCR4 expression in human
microvascular endothelial cells and human melanoma cells. Eur Cytokine
Netw 2007, 18:59-70.
37. Chi JT, Chang HY, Haraldsen G, Jahnsen FL, Troyanskaya OG, Chang DS,
Wang Z, Rockson SG, van de Rijn M, Botstein D, Brown PO: Endothelial cell
diversity revealed by global expression profiling. Proc Natl Acad Sci U S A
2003, 100:10623-10628.
38. Feil C, Augustin HG: Endothelial cells differentially express functional
CXC-chemokine receptor-4 (CXCR-4/fusin) under the control of autocrine
activity and exogenous cytokines. Biochem Biophys Res Commun 1998,
247:38-45.
39. Denton CP, Bickerstaff MC, Shiwen X, Carulli MT, Haskard DO, Dubois RM,
Black CM: Serial circulating adhesion molecule levels reflect disease
severity in systemic sclerosis. Br J Rheumatol 1995, 34:1048-1054.
40. Sollberg S, Peltonen J, Uitto J, Jimenez SA: Elevated expression of beta 1
and beta 2 integrins, intercellular adhesion molecule 1, and endothelial
leukocyte adhesion molecule 1 in the skin of patients with systemic
sclerosis of recent onset. Arthritis Rheum 1992, 35:290-298.
41. Gough PJ, Garton KJ, Wille PT, Rychlewski M, Dempsey PJ, Raines EW: A
disintegrin and metalloproteinase 10-mediated cleavage and shedding
regulates the cell surface expression of CXC chemokine ligand 16.
J Immunol 2004, 172:3678-3685.
42. Matloubian M, David A, Engel S, Ryan JE, Cyster JG: A transmembrane CXC
chemokine is a ligand for HIV-coreceptor Bonzo. Nat Immunol 2000,
1:298-304.
43. Yanaba K, Muroi E, Yoshizaki A, Hara T, Ogawa F, Shimizu K, Yozaki M,
Hasegawa M, Fujimoto M, Takehara K, Sato S: Serum CXCL16
concentrations correlate with the extent of skin sclerosis in patients
with systemic sclerosis. J Rheumatol 2009, 36:1917-1923.
44. Unutmaz D, Xiang W, Sunshine MJ, Campbell J, Butcher E, Littman DR: The
primate lentiviral receptor Bonzo/STRL33 is coordinately regulated with
CCR5 and its expression pattern is conserved between human and
mouse. J Immunol 2000, 165:3284-3292.
45. Beyer C, Schett G, Gay S, Distler O, Distler JH: Hypoxia. Hypoxia in the
pathogenesis of systemic sclerosis. Arthritis Res Ther 2009, 11:220.
doi:10.1186/ar3242
Cite this article as: Rabquer et al.: Dysregulated expression of MIG/
CXCL9, IP-10/CXCL10 and CXCL16 and their receptors in systemic
sclerosis. Arthritis Research & Therapy 2011 13:R18.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Rabquer et al. Arthritis Research & Therapy 2011, 13:R18
http://arthritis-research.com/content/13/1/R18
Page 10 of 10
